Available online on 15 Mar, 2026 at https://ijdra.com/index.php/journal

International Journal of Drug Regulatory Affairs

Published by Diva Enterprises Pvt. Ltd., New Delhi
Associated with Delhi Pharmaceutical Sciences & Research University

Review Article

Open Access

Reinventing Drug Development and Regulatory Affairs through Artificial Intelligence

Almas Nafis Shaikh*, Shoaib Ali Syed

Department of Regulatory Affairs, Dr. Vedprakash Patil Pharmacy College, Georai Tanda, Dist- Chatrapati Sambhaji Nagar, India-431105

Abstract

Drug discovery, development, and regulatory approval are traditionally lengthy, costly, and high-risk processes within the pharmaceutical industry. The integration of Artificial Intelligence (AI) offers a transformative approach to overcoming these challenges by enabling data-driven, efficient, and predictive decision-making across the drug development lifecycle. This thesis explores the role of AI technologies, including machine learning, deep learning, and natural language processing, in revolutionizing early drug discovery, preclinical and clinical development, and regulatory affairs. AI-driven methods enhance target identification, lead optimization, clinical trial design, and safety monitoring while reducing development timelines and costs. Furthermore, the study examines the growing application of AI in regulatory processes such as automated dossier review, risk assessment, and pharmacovigilance. Overall, this work highlights AI as a key enabler in modernizing pharmaceutical innovation and regulatory frameworks, ultimately improving the delivery of safe and effective therapies to patients.

Conclusion: The rapid advancement of Artificial Intelligence is fundamentally transforming drug development and regulatory affairs by addressing long-standing challenges related to time, cost, and high failure rates. AI-driven approaches enable more accurate target identification, efficient lead optimization, improved preclinical predictions, and smarter clinical trial design, ultimately enhancing decision-making across the pharmaceutical value chain. In parallel, the adoption of AI in regulatory affairs is modernizing submission processes, risk assessment, and post-marketing surveillance, leading to improved compliance, transparency, and patient safety.

Keywords: Artificial Intelligence (AI); Drug Discovery and Development; Machine Learning; Clinical Trials; Regulatory Affairs; Pharmacovigilance; Drug Approval; Digital Transformation; Pharmaceutical Industry

Article Info: Received 08 Feb 2026; Review Completed 09 Mar 2026; Accepted 13 Mar 2026

Cite this article as:
Shaikh AN, Syed SA. Reinventing Drug Development and Regulatory Affairs through Artificial Intelligence. Int. J. Drug Reg. Affairs [Internet]. 2026 Mar 15 [cited 2026 Mar 15]; 14(1):71-77. Available from: https://ijdra.com/index.php/journal/article/view/860

DOI: 10.22270/ijdra.v14i1.860
*Corresponding author. E-mail address: nafisshaikh608@gmail.com (A. N. Shaikh)

1. Introduction

Drug discovery and development represent some of the most complex, time-consuming, and resource-intensive activities within the pharmaceutical industry Traditionally, these processes have relied heavily on sequential experimentation, trial- and-error approaches, extensive laboratory validation, and multi-phase clinical trials As a result, the development of a single new drug often takes more than 10–15 years and incurs costs exceeding billions of dollars, with a high risk of failure at later stages. (1) These challenges have created an urgent need for innovative technologies capable of improving efficiency, reducing costs, and enhancing decision-making throughout the drug development lifecycle.

The emergence of Artificial Intelligence (AI) has introduced a transformative shift in how drugs are discovered, developed, and regulated AI technologies—particularly machine learning (ML), deep learning (DL), and natural language processing (NLP)—enable the rapid analysis of vast and complex datasets that are beyond the capacity of traditional analytical methods. (2) In early drug discovery, AI facilitates target identification by uncovering disease-associated genes and pathways, predicting protein structures, and modeling molecular interactions with unprecedented accuracy. (3) Additionally, AI-driven virtual screening and de novo drug design significantly accelerate the identification of promising lead compounds while minimizing reliance on costly wet-lab experiments. (4)

Beyond discovery, AI has demonstrated strong potential in optimizing preclinical studies and clinical trial design. Predictive modeling assists in toxicity assessment, pharmacokinetic profiling, and dose optimization, reducing attrition rates in later stages. (5) In clinical development, AI supports patient stratification, trial site selection, and real-time monitoring of trial data, thereby improving trial

efficiency, patient safety, and success rates. (6) These capabilities not only shorten development timelines but also contribute to more personalized and precise therapeutic interventions.

Parallel to advancements in drug development, AI is increasingly redefining the field of Regulatory Affairs. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Central Drugs Standard Control Organization (CDSCO) are exploring AI-based tools for data evaluation, automated dossier review, and risk-based decision-making. (7) AI systems can streamline regulatory submissions through intelligent document management, automated report generation, and consistency checks, enhancing compliance and transparency. (8) Furthermore, AI-driven pharmacovigilance systems enable early detection of adverse drug reactions by analyzing real-world evidence, electronic health records, and social media data, thereby strengthening post-marketing surveillance. (9)

In conclusion, the integration of Artificial Intelligence into drug development and regulatory affairs marks a paradigm shift from traditional, labor-intensive methodologies to data-driven, intelligent systems. By enhancing innovation, accuracy, and operational efficiency, AI holds the potential to reshape the pharmaceutical ecosystem, accelerate access to safe and effective medicines, and ultimately improve global patient outcomes. (10)

2. Aim and Objective of Study

2.1 Aim

The primary aim of this study is to evaluate the role of Artificial Intelligence in transforming drug development and regulatory affairs by enhancing efficiency, accuracy, and decision-making across the pharmaceutical lifecycle.

2.2 Objectives of the Study

- To study the traditional drug development and regulatory affairs processes and identify their limitations in terms of time, cost, and success rates.
- To explore the applications of Artificial Intelligence in various stages of drug development, including target identification, lead optimization, preclinical evaluation, and clinical trial design.
- To examine the role of AI in regulatory affairs, focusing on regulatory submissions, data management, compliance monitoring, and decision support systems.
- To assess the impact of AI on pharmacovigilance and post-marketing surveillance, including adverse event detection and risk management.
- To evaluate the benefits of AI integration in improving efficiency, reducing development timelines, and enhancing patient safety in pharmaceutical research and regulation.
- To identify challenges and limitations associated with AI implementation, including data quality issues, ethical concerns, regulatory acceptance, and infrastructural constraints.
- To review current global regulatory perspectives and initiatives related to the use of AI in drug development and regulatory science.
- To analyze future prospects and emerging trends of AI adoption in the pharmaceutical industry and regulatory frameworks.
- To provide recommendations for effective and responsible integration of AI in drug development and Regulatory Affairs.

3. Limitations of the Study

- **Dependence on Secondary Data:** The study is primarily based on secondary sources such as published literature, regulatory documents, review articles, and publicly available reports. Limited access to proprietary pharmaceutical and regulatory datasets may restrict the depth of real-world validation.
- **Rapid Evolution of AI Technologies:** Artificial Intelligence is a rapidly advancing field. Continuous developments in algorithms, tools, and regulatory approaches may render some findings or discussions outdated over time.
- **Lack of Quantitative Validation:** The study focuses mainly on qualitative analysis and conceptual frameworks. It does not include large-scale empirical or statistical comparisons between AI-driven and conventional drug development methodologies.
- **Regulatory Variability Across Regions:** Regulatory acceptance and implementation of AI vary significantly across global regulatory authorities such as the FDA, EMA, and CDSCO. This limits the universal applicability of regulatory insights and conclusions.
- **Limited Real-World Case Studies:** Due to confidentiality and data protection constraints, the number of publicly available real-world AI implementation case studies in drug development and regulatory affairs is limited.
- **Ethical and Data Privacy Constraints:** Ethical concerns such as algorithmic bias, transparency, explainability, and data privacy are acknowledged but not explored in extensive depth within the scope of this study.
- **Infrastructure and Skill-Based Challenges:** Practical challenges including high implementation costs, limited computational infrastructure, and the shortage of skilled AI

professionals in pharmaceutical and regulatory sectors are not comprehensively addressed.

- **Generalization of Findings:** The conclusions drawn may not be equally applicable to all pharmaceutical organizations, particularly small and medium-sized enterprises, due to differences in resources, expertise, and technological readiness.

4. Background and Related Work

- The application of Artificial Intelligence (AI) in drug discovery and development has gained substantial attention over the past decade due to its potential to overcome limitations of traditional pharmaceutical research. Multiple studies have highlighted the inefficiency of conventional drug development, characterized by high attrition rates, prolonged timelines, and escalating cost. (11) Researchers have increasingly emphasized AI as a disruptive technology capable of transforming this landscape.

- Early investigations into AI-based drug discovery focused on machine learning (ML) algorithms for quantitative structure–activity relationship (QSAR) modeling. (12) These models demonstrated improved prediction of biological activity and toxicity compared to traditional statistical approaches. (13) With advancements in computational power and data availability, deep learning (DL) techniques emerged as superior tools for molecular representation and prediction. (14)

- Several studies have demonstrated the effectiveness of AI in target identification and validation. Network-based algorithms and AI-driven genomics have enabled the identification of novel disease targets by analyzing complex biological interactions. (15,16) The introduction of AlphaFold further revolutionized protein structure prediction, enabling accurate modeling of previously unresolved protein structures. (17)

- AI-driven virtual screening and de novo drug design have been widely reported to significantly reduce the time required for lead identification. (18,19) Deep generative models, such as variational autoencoders and generative adversarial networks, have been used to design novel compounds with optimized pharmacological properties. (20) These approaches have shown promising results in early-stage discovery pipelines.

- In preclinical development, AI has been applied to predict pharmacokinetics, toxicity, and drug–drug interactions. Studies indicate that AI-based toxicity prediction models outperform traditional in vivo methods in early risk assessment. (21,21) Such predictive tools contribute to reducing animal testing and preclinical failure rates.

- Clinical development has also benefited from AI integration. Researchers have explored AI-based patient stratification, biomarker discovery, and adaptive clinical trial design to improve trial success rates. (2,,25) AI algorithms have been shown to optimize trial site selection and enhance patient recruitment efficiency. (25)

- Beyond development, AI's role in Regulatory Affairs has become increasingly prominent. Literature suggests that regulatory agencies are adopting AI for data analytics, submission review, and risk-based decision-making. (26) The U.S. FDA and EMA have published frameworks outlining the responsible use of AI and ML in regulatory science. (27,28)

- Automated regulatory document management and intelligent dossier preparation systems have been reported to improve submission accuracy and reduce review timelines. (29) NLP-based tools enable efficient extraction and summarization of regulatory data from vast document repositories. (30)

- Pharmacovigilance has emerged as one of the most impactful regulatory applications of AI. Multiple studies highlight the use of AI for signal detection from real-world data, electronic health records, and social media platforms. (31,32) These systems improve early detection of adverse drug reactions and enhance post-marketing safety surveillance.

- Despite its advantages, several authors have raised concerns regarding algorithmic bias, lack of explainability, and data quality issues. (33,34) Ethical and legal challenges related to transparency, accountability, and patient data privacy remain critical barriers to widespread AI adoption. (35)

- Recent literature emphasizes the need for harmonized global regulatory frameworks, interdisciplinary collaboration, and validation standards to ensure the safe and effective integration of AI in pharmaceutical development (37-39) Overall, existing research strongly supports AI as a transformative force, while also highlighting the need for cautious, regulated, and ethically guided implementation. (39,40)

5. Purpose of the Study, Rationale, and Justification

The pharmaceutical industry plays a critical role in improving global health by developing safe, effective, and high-quality medicines. However, drug discovery, development, and regulatory approval remain among the most complex, time- consuming, and expensive processes across scientific industries. Despite significant technological progress, the success rate of new drug candidates remains low, with high attrition occurring during preclinical and clinical phases.

Traditional drug development models rely heavily on linear workflows, extensive laboratory experimentation, and prolonged clinical trials, often resulting in escalating costs, delayed market entry, and limited patient access to innovative therapies. These persistent challenges underscore the urgent need for transformative approaches that can improve efficiency, accuracy, and decision- making across the pharmaceutical value chain.

Artificial Intelligence (AI) has emerged as a powerful technological advancement with the potential to address many of these long-standing challenges. AI-driven systems, including machine learning, deep learning, and natural language processing, enable rapid analysis of large and complex datasets, uncover hidden patterns, and generate predictive insights that surpass traditional analytical capabilities. The growing availability of biomedical big data—such as genomics, proteomics, chemical libraries, electronic health records, and real-world evidence—further amplifies the relevance of AI in pharmaceutical research and regulatory science. Consequently, there is a compelling need to systematically examine how AI can reinvent drug development and regulatory affairs, making this study both timely and necessary.

5.1 Need of the Study

The primary need for this study arises from the increasing gap between the rising demand for innovative medicines and the declining productivity of traditional drug development pipelines. With increasing disease complexity, particularly in areas such as cancer, neurological disorders, and rare diseases, conventional trial-and-error approaches are proving insufficient. AI offers opportunities to accelerate target identification, optimize lead selection, predict toxicity, and improve clinical trial design, thereby addressing inefficiencies that hinder pharmaceutical innovation. However, despite growing adoption, the integration of AI across the drug development lifecycle remains fragmented and inconsistent.

Furthermore, regulatory frameworks are evolving more slowly than technological innovation. Regulatory affairs professionals face growing challenges in managing complex datasets, ensuring compliance with rapidly changing guidelines, and maintaining transparency and traceability in submissions. The increasing volume of regulatory documentation, pharmacovigilance data, and post-marketing surveillance reports necessitates intelligent automation and decision-support tools. AI-driven regulatory solutions have the potential to streamline submissions, enhance review efficiency, and improve patient safety, but their implementation requires careful evaluation and validation. This study is therefore needed to bridge the knowledge gap between technological potential and practical regulatory application.

Another critical need for this study lies in the lack of consolidated academic literature that jointly examines AI's role in both drug development and regulatory affairs. Most existing studies focus on isolated applications, such as AI in drug discovery or AI in clinical trials, with limited attention to regulatory implications. A holistic assessment is essential to understand how AI-driven innovation can be aligned with regulatory expectations, ethical standards, and patient-centric outcomes.

5.2 Rationale of the Study

The rationale for this study is grounded in the transformative potential of AI to shift pharmaceutical research and regulation from reactive, resource-intensive processes to proactive, data-driven systems. AI's ability to integrate multidisciplinary datasets enables earlier and more accurate decision-making, reducing uncertainty and minimizing costly late-stage failures. By applying predictive analytics and automation, AI can significantly reduce development timelines, optimize resource utilization, and enhance scientific rigor.

In regulatory affairs, the rationale for exploring AI integration is particularly strong. Regulatory agencies worldwide are increasingly recognizing the value of AI in regulatory science, including benefit–risk assessment, pharmacovigilance, and post-market surveillance. However, regulatory acceptance of AI varies across regions, and concerns regarding transparency, explainability, and accountability persist. This study seeks to rationalize AI adoption by evaluating its benefits alongside its limitations, ethical concerns, and regulatory readiness.

Additionally, there is a growing demand for skilled professionals who can operate at the intersection of pharmaceutical science, data analytics, and regulatory compliance. By examining AI's impact on drug development and regulatory affairs, this study provides a rationale for curriculum development, workforce upskilling, and organizational transformation within the pharmaceutical sector.

5.3 Justification of the Study

This study is justified on scientific, industrial, regulatory, and societal grounds. From a scientific perspective, AI represents a paradigm shift in how biological complexity is understood and leveraged for therapeutic innovation. Understanding AI- driven methodologies enables researchers to design more rational, efficient, and reproducible drug development strategies. From an industrial standpoint, pharmaceutical companies are under immense pressure to reduce R&D costs while increasing productivity. AI-based approaches offer competitive advantages by enabling faster go/no-go decisions, reducing failure rates, and improving portfolio management. A structured evaluation of AI applications helps organizations make informed investment and implementation decisions.

From a regulatory perspective, the justification for this study lies in the increasing complexity of regulatory submissions and the growing emphasis on real-world evidence and lifecycle-based regulation. AI can support regulatory authorities by enhancing review efficiency, improving safety signal detection, and enabling adaptive regulatory models. However, the lack of standardized validation frameworks necessitates

academic research to guide evidence-based regulatory acceptance.

Societally, the study is justified by the need to improve patient outcomes and access to medicines. Faster development timelines, improved safety monitoring, and personalized therapies directly benefit public health. By evaluating AI's role in ensuring drug quality, safety, and efficacy, this study aligns with global healthcare priorities.

Moreover, ethical and legal concerns related to AI—such as data privacy, algorithmic bias, and explainability—require careful examination. This study justifies its relevance by addressing these concerns within the pharmaceutical and regulatory context, promoting responsible and transparent AI adoption.

6. Study approach

The present study is designed as a **descriptive and analytical review-based study** focusing on the application of Artificial

Intelligence (AI) in drug development and regulatory affairs. The study systematically analyzes existing scientific literature, regulatory guidelines, and industry reports to evaluate current practices, benefits, limitations, and future prospects of AI integration in the pharmaceutical sector.

6.1 Data Collection and Organization

Relevant information was extracted from selected sources and organized into thematic categories, including:

- AI in drug discovery and preclinical development
- AI in clinical trial design and management
- AI applications in regulatory submissions and compliance
- AI-driven pharmacovigilance and post-marketing surveillance
- Ethical, legal, and regulatory challenges associated with AI

6.2 Data Analysis

The collected data were analyzed qualitatively using a comparative and thematic approach. Traditional drug development and regulatory processes were compared with AI-driven approaches to assess improvements in efficiency, accuracy, and decision-making. Key benefits, limitations, and regulatory challenges were identified and interpreted in relation to study objectives.

6.3 Ethical Considerations

As this study is based on secondary data analysis of publicly available sources, no direct ethical approval was required. However, ethical principles such as proper citation, avoidance of plagiarism, and responsible interpretation of findings were strictly followed.

6.4 Study Limitations

The methodology is limited by reliance on secondary data and qualitative analysis. Lack of access to proprietary datasets and real-world AI implementation data may limit empirical validation of finding.

7. Conclusion

The findings of this study highlight the transformative potential of Artificial Intelligence (AI) in reshaping the landscape of drug development and regulatory affairs. Traditional drug development processes are often time-consuming, resource-intensive, and associated with high failure rates. This research demonstrates that integrating AI technologies can significantly address these limitations by accelerating drug discovery, enhancing preclinical analysis, and improving the efficiency and reliability of clinical trials. Furthermore, the study emphasizes the growing role of AI in regulatory affairs, particularly in streamlining regulatory submissions, managing large volumes of scientific data, and supporting regulatory decision-making. AI-driven tools also show promising capabilities in pharmacovigilance and post-marketing surveillance by enabling faster signal detection and more effective analysis of real-world data, ultimately contributing to improved patient safety. The integration of AI offers several key advantages, including reduced development timelines, enhanced data accuracy, cost efficiency, and better risk management throughout the drug lifecycle. However, the research also identifies important challenges such as data quality concerns, ethical considerations, regulatory acceptance, and the need for robust technological infrastructure. Addressing these challenges is essential to ensure the responsible and effective implementation of AI in pharmaceutical systems. In addition, the study provides insights into the evolving global regulatory perspectives on AI adoption, highlighting both common approaches and differences among regulatory authorities. These insights underscore the need for international collaboration and harmonization to support innovation while maintaining regulatory standards.

Acknowledgements:

I would like to express my gratitude to International Journal of Drug Regulatory Affairs who gave me the opportunity to publish the article.

Conflict of Interest

he author declares that there is no conflict of interest regarding the publication of this article.

Financial Disclosure statement:

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reference

1. Bate A, Evans SJW. Quantitative signal detection using

spontaneous ADR reporting. Drug Saf [Internet]. 2009 Jan [cited 2026 Mar];32(1):17–29. Available from: https://pubmed.ncbi.nlm.nih.gov/19132802/
2. Todeschini R, Consonni V. Molecular descriptors: theory and applications. Weinheim: Wiley-VCH; 2009.
3. Miner G, Elder J, Fast A, Hill T, Nisbet R, Delen D. Practical text mining and statistical analysis for non-structured text data applications. Oxford: Academic Press; 2012.
4. Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M, et al. QSAR modeling: where have you been? Where are you going to? J Med Chem [Internet]. 2014 Jun 12 [cited 2026 Mar 17];57(12):4977–5010. Available from: https://pubmed.ncbi.nlm.nih.gov/24351051/
5. Greene CS, Penrod NM, Kiralis J, Moore JH. Exploiting genetic interactions in network biology. Nat Rev Genet [Internet]. 2015 Jul [cited 2026 Mar 17];16(7):409–423. Available from: https://pubmed.ncbi.nlm.nih.gov/26007769/
6. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature [Internet]. 2015 May 28 [cited 2026 Mar 17];521(7553):436–444. Available from: https://pubmed.ncbi.nlm.nih.gov/26017442/
7. Lavecchia A. Machine-learning approaches in drug discovery: methods and applications. Drug Discov Today [Internet]. 2015 Mar [cited 2026 Mar 17];20(3):318–331. Available from: https://pubmed.ncbi.nlm.nih.gov/25448759/
8. Sarker A, Ginn R, Nikfarjam A, O'Connor K, Smith K, Jayaraman S, et al. Social media mining for adverse drug event detection. J Biomed Inform [Internet]. 2015 Apr [cited 2026 Mar 17];54:202–212. Available from: https://pubmed.ncbi.nlm.nih.gov/25655292/
9. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ [Internet]. 2016 May [cited 2026 Mar 17];47:20–33. Available from: https://pubmed.ncbi.nlm.nih.gov/26928437/
10. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ [Internet]. 2016 May [cited 2026 Mar 17];47:20–33. Available from: https://pubmed.ncbi.nlm.nih.gov/26928437/
11. Mayr A, Klambauer G, Unterthiner T, Hochreiter S. Large-scale comparison of machine learning methods for drug target prediction. Chem Res Toxicol [Internet]. 2016 Feb [cited 2026 Mar 17];29(2):154–163. Available from: https://pubmed.ncbi.nlm.nih.gov/26740092/
12. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today [Internet]. 2018 Jun [cited 2026 Mar 17];23(6):1241–1250. Available from: https://pubmed.ncbi.nlm.nih.gov/29366762/
13. Wu Z, Ramsundar B, Feinberg EN, Gomes J, Geniesse C, Pappu AS, et al. MoleculeNet: a benchmark for molecular machine learning. Chem Sci [Internet]. 2018 Jan [cited 2026 Mar 17];9(2):513–530. Available from: https://pubmed.ncbi.nlm.nih.gov/29629118/
14. Zitnik M, Agrawal M, Leskovec J. Modeling polypharmacy side effects with graph convolutional networks. Nat Biotechnol [Internet]. 2018 Jan [cited 2026 Mar 17];36(1):15–23. Available from: https://pubmed.ncbi.nlm.nih.gov/29227477/
15. Mesko B. The guide to artificial intelligence in healthcare. CreateSpace Independent Publishing; 2018.
16. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov [Internet]. 2019 Jun [cited 2026 Mar 17];18(6):463–477. Available from: https://www.semanticscholar.org/paper/The-rise-of-deep-learning-in-drug-discovery.-Chen-Engkvist/89213307256d538942fab6b4ac7ab0dee6936582
17. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med [Internet]. 2019 Jan [cited 2026 Mar 17];25(1):44–56. Available from: https://pubmed.ncbi.nlm.nih.gov/30617339/
18. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci [Internet]. 2019 Aug [cited 2026 Mar 17];40(8):577–591. Available from: https://pubmed.ncbi.nlm.nih.gov/31328863/
19. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today [Internet]. 2019 Mar [cited 2026 Mar 17];24(3):773–780. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1359644619301849
20. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci [Internet]. 2019 Aug [cited 2026 Mar 17];40(8):577–591. Available from: https://www.fda.gov/media/167973/download
21. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today [Internet]. 2019 Mar [cited 2026 Mar 17];24(3):773–780. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1359644619301849
22. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science [Internet]. 2019 Oct [cited 2026 Mar 17];366(6464):447–453. Available from: https://pubmed.ncbi.nlm.nih.gov/31649194/
23. Rudin C. Stop explaining black-box machine learning models for high-stakes decisions and use interpretable models instead. Nat Mach Intell [Internet]. 2019 May [cited 2026 Mar 17];1(5):206–215. Available from: https://www.nature.com/articles/s42256-019-0048-x
24. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med [Internet]. 2019 Jan [cited 2026 Mar 17];25(1):44–56. Available from: https://pubmed.ncbi.nlm.nih.gov/30617339/
25. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today [Internet]. 2019 Mar [cited 2026 Mar 17];24(3):773–780. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1359644619301849
26. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med [Internet]. 2019 Jan [cited 2026 Mar 17];25(1):44–56. Available from: https://pubmed.ncbi.nlm.nih.gov/30617339/
27. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov [Internet]. 2019 Jun [cited 2026 Mar 17];18(6):463–477. Available from: https://pubmed.ncbi.nlm.nih.gov/30976107/
28. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MV, Aladinskiy VA, Aladinskaya AV, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol [Internet]. 2019 Sep [cited 2026 Mar 17];37(9):1038–1040. Available from: https://pubmed.ncbi.nlm.nih.gov/31477816/
29. Woodcock J, et al. Innovative regulatory science approaches. Clin Pharmacol Ther [Internet]. 2020 Jan [cited 2026 Mar 17];107(Suppl 1):7–12. Available from: https://pubmed.ncbi.nlm.nih.gov/31925877/

30. Walters WP, Murcko M. Assessing the impact of generative AI on medicinal chemistry. Nat Biotechnol [Internet]. 2020 Sep [cited 2026 Mar 17];38(9):1128–1131. Available from: https://pubmed.ncbi.nlm.nih.gov/32839510/
31. European Medicines Agency. Regulatory science strategy to 2025 [Internet]. Amsterdam: EMA; 2020 [cited 2026 Mar 17]. Available from: https://www.ema.europa.eu/en/about-us/what-we-do/regulatory-science-strategy-2025
32. European Medicines Agency. Regulatory science strategy to 2025 [Internet]. Amsterdam: EMA; 2020 [cited 2026 Mar 17]. Available from: https://www.ema.europa.eu/en/about-us/what-we-do/regulatory-science-strategy-2025
33. IQVIA Institute. The use of artificial intelligence in clinical trials [Internet]. Durham (NC): IQVIA; 2020 [cited 2026 Mar 17]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/the-use-of-ai-in-clinical-trials
34. Bate A, Hobbiger SF. Artificial intelligence, real-world automation and the safety of medicines. Drug Saf [Internet]. 2021 Feb [cited 2026 Mar 17];44(2):125–132. Available from: https://pubmed.ncbi.nlm.nih.gov/33387379/
35. Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: what's realistic, what are illusions? Drug Discov Today [Internet]. 2021 Feb [cited 2026 Mar 17];26(2):511–524. Available from: https://pubmed.ncbi.nlm.nih.gov/33232777/
36. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature [Internet]. 2021 Aug [cited 2026 Mar 17];596(7873):583–589. Available from: https://pubmed.ncbi.nlm.nih.gov/34265844/
37. Organisation for Economic Co-operation and Development. AI in health care [Internet]. Paris: OECD Publishing; 2021 [cited 2026 Mar 17]. Available from: https://www.oecd.org/health/ai-in-health.htm
38. U.S. Food and Drug Administration. Artificial intelligence and machine learning in software as a medical device: discussion paper [Internet]. Silver Spring (MD): FDA; 2021 [cited 2026 Mar 17]. Available from: https://www.fda.gov/media/167973/download
39. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ [Internet]. 2016 May [cited 2026 Mar 17];47:20–33. Available from: https://pubmed.ncbi.nlm.nih.gov/26928437/
40. Price WN, Cohen IG. Privacy in the age of medical AI. Duke Law J. 2019;69(1):46–116